{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"041-685-941-735-511","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"041-685-941-735-511"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11916,"type":"PATENT","title":"Georgetown University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3191,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8504,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Georgetown Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3015
Search Applicants and Owners separately:Georgetown Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3015
a) a DNA having a nucleotide sequence consisting essentially of the nucleotide sequence of SEQ ID NO: 11 and\n
b) a DNA encoding protein consisting essentially of the amino acid sequence of SEQ ID NO: 12."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A protein encoded by the DNA of claim 4."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["An isolated and purified DNA selected from the group consisting of\n
a) a DNA having a nucleotide sequence consisting essentially of the nucleotide sequence of SEQ ID NO: 13 and\n
b) a DNA encoding protein consisting essentially of the amino acid sequence of SEQ ID NO: 14."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["An isolated protein comprising an amino acid sequence of murine SPHK2 consisting essentially of SEQ ID NO: 12."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["An isolated and purified DNA which encodes a protein of a sphingosine kinase type 2 isoform, said DNA comprising a sequence selected from the group consisting of the sequence of Genbank Accession No. bankit325787 and the sequence of Genbank Accession No. bankit325752."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A recombinant DNA construct comprising:\n
(a) a vector and\n
(b) the DNA of claim 2."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 9, wherein said vector is an expression vector."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 9, wherein said vector is a prokaryotic vector."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 9, wherein said vector is a eukaryotic vector."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A host cell transformed with the recombinant DNA construct according to claim 9."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The host cell according to claim 13, wherein said cell is prokaryotic."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The host cell according to claim 13, wherein said cell is eukaryotic."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A recombinant DNA construct comprising:\n
(a) a vector and\n
(b) the DNA of claim 2."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 16, wherein said vector is an expression vector."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 16, wherein said vector is a prokaryotic vector."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The recombinant DNA construct according to claim 16, wherein said vector is a eukaryotic vector."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A host cell transformed with the recombinant DNA construct according to claim 16."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The host cell according to claim 20, wherein said cell is prokaryotic."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The host cell according to claim 20, wherein said cell is eukaryotic."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A method for producing a mouse sphingosine kinase type 2 isoform protein which comprises culturing the host cell according to claim 13, under conditions such that an isolated mouse sphingosine kinase type 2 isoform DNA is expressed and said mouse sphingosine kinase type 2 isoform protein is thereby produced."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A method for producing a human sphingosine kinase type 2 isoform protein which comprises culturing the host cell according to claim 20, under conditions such that an isolated human sphingosine kinase type 2 isoform DNA is expressed and said human sphingosine kinase type 2 isoform protein is thereby produced."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method for detecting an agent or a drug which inhibits or promotes an enzymatic activity of a sphingosine kinase type 2 isoform comprising:\n
(i) providing a recombinant DNA construct comprising a vector and a DNA into a cell such that a sphingosine kinase type 2 isoform is produced in said cell, wherein said DNA is selected from the group consisting of\n
(a) a DNA having a nucleotide sequence consisting essentially of the nucleotide sequence of SEQ ID NO: 13 and\n
(b) a DNA encoding protein consisting essentially of the amino acid sequence of SEQ ID NO: 14;\n
(ii) adding at least one drug or agent to said cell, and\n
(iii) detecting whether or not said drug or agent inhibits or promotes the enzymatic activity of the sphingosine kinase type 2 isoform by measuring sphingosine kinase type 2-dependent phosphorylation of lipids in said cell and comparing the resultant measurement to a control which did not receive said drug or agent, wherein a decrease in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids in said cell as compared to the control indicates a stimulatory drug or agent."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A method of regulating a biological process in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the protein according to claim 6."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein the mammal is a human."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein the biological process is selected from the group consisting of mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis and an inflammatory response."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein the biological process is angiogenesis."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a protein according to claim 6."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 30, wherein the mammal is a human."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal in need thereof a pharmaceutically effective amount of an antibody to a protein according to claim 6."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 32, wherein the mammal is a human."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of an antibody to a protein according to claim 6."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 34, wherein the mammal is a human."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35, wherein the disease is cancer."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or ameliorating a disease resulting from increased cell death or decreased cell proliferation comprising a pharmaceutically effective amount of a protein according to claim 6, and a pharmaceutically acceptable carrier."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of developmental retardation in a human comprising administering to a human in need thereof a pharmaceutically effective amount of the protein according to claim 6."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["A method for screening agents or drugs which reduce or eliminate sphingosine kinase type 2 activity, the method comprising detecting a decrease in sphingosine kinase type 2 enzyme activity in the presence of said agent or drug."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["A method for detecting the presence of a sphingosine kinase type 2 isoform in a sample comprising\n
(i) contacting a sample with an antibody which recognize sphingosine kinase type 2; and\n
(ii) detecting the presence or absence of a complex formed between sphingosine kinase type 2 and an antibody specific therefor."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["A method for detecting sphingosine kinase type 2 in a sample comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay and detecting for the presence of sphingosine kinase type 2."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["A diagnostic kit for detecting sphingosine kinase type 2 RNA/cDNA in a sample comprising one or more containers including primers or nucleotides specific for sphingosine kinase type 2 RNA or cDNA suitable for hybridization to sphingosine kinase type 2 RNA or cDNA and/or amplification of sphingosine kinase type 2 RNA or cDNA and suitable ancillary reagents."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["A method for detecting an agent or a drug which inhibits or promotes an enzymatic activity of a sphingosine kinase type 2 isoform comprising:\n
(i) contacting a sphingosine kinase type 2 isoform protein and lipids in the presence of at least one drug or agent, wherein the sphingosine kinase type 2 isoform protein is selected from the group consisting of\n
(a) a protein encoded by DNA having a nucleotide sequence consisting essentially of the nucleotide sequence of SEQ ID NO: 13 and\n
(b) a protein consisting essentially of the amino acid sequence of SEQ ID NO: 14;\n
(ii) detecting whether or not said drug or agent inhibits or promotes the enzymatic activity of the sphingosine kinase type 2 isoform by measuring sphingosine kinase-dependent phosphorylation of the lipids and comparing the resultant measurement to a control which did not receive the drug or agent, wherein a decrease in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids as compared to the control indicates a stimulatory drug or agent."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["A recombinant DNA construct comprising:\n
(a) a vector and\n
(b) the DNA of claim 4."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["A recombinant DNA construct comprising:\n
(a) a vector and\n
(b) the DNA of claim 5."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["An antibody specific for a protein according to claim 6."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The antibody according to claim 46, wherein the antibody is a polyclonal antibody."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The antibody according to claim 46, wherein the antibody is a monoclonal antibody."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["A method of regulating a biological process in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the protein according to claim 7."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 49, wherein the mammal is a human."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a protein according to claim 7."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 51, wherein the mammal is a human."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal in need thereof a pharmaceutically effective amount of an antibody to a protein according to claim 7."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 53, wherein the mammal is a human."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of an antibody to a protein according to claim 7."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 55, wherein the mammal is a human."],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["An antibody specific for a protein according to claim 7."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["The antibody according to claim 57, wherein the antibody is a polyclonal antibody."],"number":58,"annotation":false,"title":false,"claim":true},{"lines":["The antibody according to claim 57, wherein the antibody is a monoclonal antibody."],"number":59,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}